This report was first published by Endpoints News. To see the original version, click here
Novartis will pay $100 million in upfront and pre-IND milestone payments to tap into a macrocyclic peptide platform from Unnatural Products, a deal that could lead to new cardiovascular disease medicines.
The move allows the Swiss pharma giant to delve into a niche but growing area of drug R&D that seeks to combine the precision and potency of biologics with the easier-to-use delivery of oral medicines.
您已阅读18%（495字），剩余82%（2289字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。